AI in Biopharma Manufacturing: Are We There Yet? podcast

Data: Are My Data Fit for Use?

0:00
35:33
Rewind 15 seconds
Fast Forward 15 seconds
Every framework this season assumes the data under the model are trustworthy. Sam and Sarah read what the rulebook actually requires: ALCOA and its pluses from FDA's 2018 Data Integrity Q&A, PIC/S PI 041 and the Annex 11 revision; FDA's 2025 'fit for use', which adds relevance to reliability; and the data-governance clauses of the AI Act, EMA's reflection paper and draft Annex 22. The Annex 11 revision turns the training-data pipeline into a GMP computerised system, with validated transfers, unique accounts, audit trails and backup. Then the gap: nobody says how to get from a historian, a batch record and a LIMS to a fit-for-use dataset. The soft sensor's training set is interrogated attribute by attribute, the batch model's golden batches become exclusion decisions, the camera's labels and vials get their clauses, and the agentic assistant's data turn out to be documents, versions and all. Researched, scripted and voiced by AI systems under Jack Prior's direction. Sam and Sarah are AI characters; nothing in the episode is Jack speaking, and none of it is a statement of his views or his employer's. Generative AI can be confidently wrong — check the sources. Corrections: [email protected]. Transcript: https://jackprior.ai/podcast/transcript/06-data.html Documents discussed: Annex 11 — Computerised Systems (revision): https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-4-annex_en Data Integrity and Compliance with Drug CGMP Q&A: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers PI 041-1: https://picscheme.org/docview/4234 Considerations for the Use of AI to Support Regulatory Decision-Making for Drug and Biological Products: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological Regulation (EU) 2024/1689 — AI Act: https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng Reflection Paper on the Use of AI in the Medicinal Product Lifecycle: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf Annex 22 — Artificial Intelligence: https://picscheme.org/docview/9715 AI CMC Regulatory Landscape: https://jackprior.ai/ai-cmc-landscape/ Fact check: 69 factual claims in this episode were checked against the source documents by an independent AI pass: 65 are supported by the primary text, 4 are confirmed by official web sources, 0 rest on secondary sources or are hedged as such (listed in the report), 0 open. Full report: https://jackprior.ai/podcast/factcheck/06-data.html

More episodes from "AI in Biopharma Manufacturing: Are We There Yet?"